- ¥231bn
- ¥159bn
- ¥171bn
2022 6-month group forecast(IFRS)
2022 6-month group forecast(IFRS)
Table: Nippon Shinyaku -Q1 group results (IFRS)
Table: Nippon Shinyaku -2021/22 group results (IFRS)
Table: Nippon Shinyaku -2021/22 group results
Table: Nippon Shinyaku -2021/22 parent results
Table: Nippon Shinyaku - 9-MTH group results
Capricor Therapeutics jumps on agreement with Nippon Shinyaku for muscle disorder therapy
Brief: Capricor Says Co,Nippon Enter Partnership For Commercialization,Distribution Of Cap-1002 In U.S.
Brief: Dynacure Announces Strategic Collaboration And Option Agreement With Nippon Shinyaku
Table: Nippon Shinyaku - 6-MTH group results
Table: Nippon Shinyaku -Q1 group results
Table: Nippon Shinyaku -2020/21 group results
Table: Nippon Shinyaku -2020/21 parent results
Table: Nippon Shinyaku - 9-MTH group results
Table: Nippon Shinyaku - 6-MTH group results
Brief: NS Pharma Says Viltepso (Viltolarsen) Injection Now Commercially Available In U.S.
Brief: FDA Approves Targeted Treatment For Rare Duchenne Muscular Dystrophy Mutation
Table: Nippon Shinyaku -Q1 group results